We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Vicotex

Download Mobile App




Immune Signature Predicts Poor Outcome in Influenza Patients

By LabMedica International staff writers
Posted on 27 Feb 2014
A signature immune response has been identified that might help doctors identify which newly diagnosed influenza patients are most likely to develop severe symptoms and suffer poor outcomes.

Children are an at-risk population for developing complications following influenza infection, but immunologic correlates of disease severity are not understood and it has been hypothesized that innate cellular immune responses at the site of infection would correlate with disease outcome.

Scientists at St. More...
Jude Children’s Research Hospital (Memphis, TN, USA) conducted an observational cohort study with longitudinal sampling of peripheral and mucosal sites in 84 naturally influenza-infected individuals, including infants. Cellular responses, viral loads, and cytokines were quantified from nasal lavages and blood, and correlated to clinical severity. Sampling began when patients sought medical attention for influenza symptoms, and was repeated on days 3, 7, 10, and 28. Along with measuring levels of influenza virus in the nose and sinuses, researchers measured 42 cytokines and antibodies against circulating influenza viruses.

The testing showed children and adults were equally successful at eliminating the virus regardless of the subtype. In fact, based on cytokine levels in the blood, nose, and sinuses of patients, children mounted a more aggressive inflammatory response than adults. Adjusting for age and viral load, an innate immune profile characterized by increased nasal lavage monocyte chemotactic protein-3, interferon (IFN)-α2, and plasma interleukin 10 (IL-10) levels at enrollment predicted progression to severe disease. Increased plasma IL-10, monocyte chemotactic protein-3, and IL-6 levels predicted hospitalization.

Christine Oshansky, PhD, the senior author said, “The fact that the innate immune response was stronger in the airways of children than adults was a surprise. Previous studies using different measures reported that children mounted a weaker immune response. In this study, the hyperactive immune response diminished with age, but it may help explain why toddlers and infants are more likely to develop severe symptoms. Normal genetic variation might play a role in the innate immune response.” The study was published on February 15, 2014, in the American Journal of Respiratory and Critical Care Medicine.

Related Links:

St. Jude Children’s Research Hospital



Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Quantitative POC Immunoassay Analyzer
EASY READER+
Gold Member
Blood-Based Protein Biomarker Solution for Alzheimer's Disease
BG-DTi2000.
CMV CLIA Diagnostic
CLIA CMV IgA Screen Group
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image Credit: Shutterstock

Blood Test Could Guide Drug Selection to Prevent Repeat Heart Attacks and Strokes

Secondary prevention after myocardial infarction or stroke relies on antiplatelet therapy, yet responses vary widely and both recurrent thrombosis and bleeding remain persistent risks. In the United Kingdom,... Read more

Molecular Diagnostics

view channel
Image: The Avantect Pancreatic Cancer Test combines epigenomic, genomic, and glycan biomarkers with machine learning to detect pancreatic cancer-associated signals in blood (Photo courtesy of ClearNote Health)

Multiomic Blood Test Supports Noninvasive Monitoring and Subtyping in Pancreatic Cancer

Pancreatic ductal adenocarcinoma remains difficult to detect early and monitor during treatment, particularly in patients with homologous recombination defects. Clinicians also have limited noninvasive... Read more

Microbiology

view channel
Image: Graphical Abstract (Jose A. Céspedes, Maria I. Montañez, Isabel M. Jiménez, et al. Magnetic nanoparticles enable clinically relevant in vitro diagnosis of beta-lactam allergy. Materials Today Bio (2026). DOI: 10.1016/j.mtbio.2026.103356)

Magnetic Nanoparticles Enable More Sensitive Beta-Lactam Allergy Testing

Penicillin allergy labels are common in clinical practice, yet many are incorrect and can lead to suboptimal antibiotic choices. Although 8%–25% of people report a penicillin allergy, only 1%–10% are truly... Read more

Pathology

view channel
Image: A new study demonstrates that vascular features in colorectal tumors could serve as prognostic biomarkers of disease outcome. (Image Credit: iStock)

Tumor Blood Vessel Features May Help Predict Colorectal Cancer Survival

Colorectal cancer outcomes vary widely, and tumor biology remains a key determinant of prognosis. Because neoplasms depend on a vascular supply, differences in intratumoral vessels may influence survival.... Read more

Technology

view channel
Image: ADLM recommends that emerging AI tools follow the same professional oversight, quality, validation, and monitoring standards as traditional clinical testing within CLIA’s existing framework (Image Credit: Adobe Stock)

ADLM Calls for CLIA Updates to Support Safe AI Use in Laboratory Medicine

Clinical laboratories increasingly use artificial intelligence to verify, interpret, and report results, but safeguards under the Clinical Laboratory Improvement Amendments (CLIA) were designed in 1992.... Read more

Industry

view channel
Image Credit: Adobe Stock

Mayo Clinic and Thermo Fisher Launch Multi-Omics Venture to Identify Early Disease Signals

Many diseases begin developing years before symptoms emerge, making early detection difficult for healthcare systems and clinical laboratories. Linking molecular changes with longitudinal health data could... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.